



Genetic Analysis AS enters an agreement with Hausen Bernstein Co. Ltd. to launch GA-map® technology in Thailand

OSLO, NORWAY – November 30, 2022: Molecular diagnostics specialist, Genetic Analysis AS (“GA”) has entered a tech transfer and distribution agreement with Hausen Bernstein Co. Ltd. (“HB”), a Bangkok-based fast-growing medical technology company with a diagnostic laboratory facility in Bangkok and a distribution business of diagnostic products in Thailand. HB will launch the GA-map® Dysbiosis Test from their molecular lab in Bangkok and market the GA-map® products in wider Thailand – making it the first CE-IVD marked standardized gut microbiome test on this market. The service offering will mainly target private and public clinical laboratories and a commercial launch is expected in Q1 2023.

Ronny Hermansen, CEO, Genetic Analysis, comments:

“GA is proud to have Hausen Bernstein as a partner in Thailand and is thrilled to see that our GA-map® platform gets recognition from customers globally. The GA-map® platform offers a fast turnaround lab testing service with an integrated software algorithm for immediate result presentation of your microbiome analysis. The GA-map® platform will enable Hausen Bernstein to supply the highest quality microbiome tests in Thailand”.

The market demand for gut microbiome assessments is rapidly increasing globally in private healthcare services, medical clinics, and academic research with a focus on identifying and categorizing the patient’s dysbiosis. Together with HB, GA can now offer its CE-IVD marked standardized gut microbiome testing platform to the Thai market to meet the growing interest and raise awareness of dysbiosis.

Dr. Banlang Luangwaranan, CEO, Hausen Bernstein, comments:

“HB are excited to offer the GA-map Microbiome testing platform to the Thai market, as we see that the focus on our Microbiome balance is rapidly increasing as people experience more and more gut-related problems. GA-map will be a great complement to our growing business of food allergy testing. The core value of HB is to offer the highest quality products to our customers, and we are proud to add GA-map to our portfolio of high-end products.”

For further information, please contact:

Ronny Hermansen, CEO

E-mail: rh@genetic-analysis.com

Eilert Aamodt, Chief Financial Officer

E-mail: ea@genetic-analysis.com

About Hausen Bernstein Co. Ltd.

Hausen Bernstein Co was founded in 2003 and is a fast-growing medical technology company with a core focus on supplying the highest standard products, services, and technical support to the Thai health care system. Hausen Bernstein is also distributing products from more than 20 renowned suppliers from Europe, the US, Japan, Singapore, and China.

On the diagnostic side (IVD), products are covering areas within autoimmune diseases, allergy diagnostic testing, point-of-care testing for respiratory infections, gastrointestinal disease, food intolerance tests, and vector-borne

Pressmeddelande

2022-11-30



diseases. Also, molecular diagnostic testing in infectious diseases and cancer diagnosis. Other than IVD products, Hausen Bernstein provides unique medical devices for the health and wellness sector.

Hausen Bernstein products are positioned as the highest standard products in each field, and its customers are the top-ranked healthcare units in Thailand, medical schools, renowned private hospitals, hospital chains, and private labs. The sales team covers the whole territory of Thailand.

For more information: <https://www.hausen.co.th/>

About Genetic Analysis

Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 10 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting-edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA's vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to helping unlock and restore the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.

For more information: www.genetic-analysis.com